Allogene Therapeutics

ALLO

Biotechnology · Healthcare

Price

$1.79

+0.00 (+0.00%)

Market Cap

$436.5M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+62.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 135.8M (2021) → 220.6M (2025)

Allogene Therapeutics is a clinical-stage biotech company working on cancer treatments. Instead of using a patient's own cells, Allogene makes "off-the-shelf" CAR-T cell therapies — engineered immune cells grown in a lab that can be stored and shipped to hospitals ready to use. The company focuses on blood cancers like leukemia and lymphoma, and its main customers would be hospitals and cancer treatment centers.

Allogene does not yet sell any approved products, so it earns no revenue from sales. It funds its research through cash reserves and occasional stock or partnership deals. The company operates primarily in the United States and has a market cap of roughly $500 million. Its key differentiator is the allogeneic approach — using donor cells rather than a patient's own — which could make CAR-T therapy faster and cheaper to deliver. The biggest risk is clinical: its lead drugs must still prove they work safely in late-stage trials before any path to approval or revenue exists.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+35.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$150M/ year

↓ Declining (-22% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

33.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~7 months

$30M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Allogene Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-13.1%

Weak — -13.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.26

Conservative — low debt load (0.26)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial